A Compassionate Use study of MAT2203 for the treatment of Rhodotorula mucilaginosa (R. mucilaginosa) Fungal Infection

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2024 According to a Matinas Biopharma media release, company announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales.
22 Mar 2024 According to Matinas Biopharma media release, Three Patients with Invasive Fusarium Infection following treatment with MAT2203 achieved Complete Clinical Response .
26 Feb 2024 Results presented in a Matinas Biopharma Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com